Giotrif
What Giotrif is used for
Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Giotrif
- Active substance
- afatinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE13
- Marketing authorisation holder
- Boehringer Ingelheim International GmbH
- Authorised in the EU since
- 2013
Official information
In the USA
Same active substance: Gilotrif
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Giotrif used for?
Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
What is the active substance in Giotrif?
Giotrif contains afatinib.
Who makes Giotrif?
The EU marketing authorisation holder is Boehringer Ingelheim International GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU